Senior VP and Treasurer Daniel Jorndt, 48, named president and chief operating officer. He succeeds Fred Canning, 65, who is retiring Feb. 1. Charles Hunter, exec VP, is named vice chairman and will continue as chief financial officer. Firm announces Oct. 11 that fiscal 1989 prescription revenues rose 20% to $1.6 bil. Pharmacy operations made up 30% of overall sales, which were $5.4 mil. Firm opened 89 new stores in fiscal 1989 (ended Aug. 31) and renovated 157 stores, including 99 pharmacies. Plans call for 180 remodelings in fiscal 1990.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.